Viela Bio (Nasdaq: VIE) has received FDA approval for UPLIZNATM (inebilizumab-cdon) aimed at treating adults with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-AQP4 antibodies. This twice-yearly maintenance therapy shows significant efficacy in reducing NMOSD attacks, as evidenced by the pivotal N-MOmentum trial, where 89% of patients remained relapse-free after treatment. The approval reflects the unmet need in NMOSD management, which affects approximately 10,000 individuals in the U.S.
Viela Bio, Inc. (Nasdaq: VIE) has priced an underwritten public offering of 3,600,000 shares of common stock at $47.00 per share, aiming for gross proceeds of approximately $169 million, before expenses. The offering includes a 30-day option for underwriters to purchase an additional 540,000 shares. Proceeds will support the commercialization of inebilizumab for NMOSD and advance clinical development of pipeline candidates. The offering is expected to close on or about June 1, 2020.
Viela Bio (Nasdaq: VIE) announced plans to offer and sell 3,000,000 shares of its common stock in an underwritten public offering, with an additional 450,000 shares available from selling stockholders. The offering is led by Morgan Stanley and Goldman Sachs. Proceeds will support the commercialization of inebilizumab for NMOSD, ongoing clinical development of inebilizumab for other indications, and other pipeline candidates like VIB4920 and VIB7734. A registration statement was filed with the SEC on May 26, 2020.
Viela Bio (Nasdaq: VIE) reported Q1 2020 financial results, revealing a net loss of $40.8 million, up from $21.0 million in Q1 2019. The company has $335.2 million in cash and no debt. Anticipating FDA approval for inebilizumab by June 11, 2020, Viela is prepping for its commercial launch. Positive interim results were announced for VIB7734 in cutaneous lupus erythematosus, while trials for VIB4920 are on hold due to COVID-19. Viela expects its financial resources to last through mid-2022.
Viela Bio reported positive interim Phase 1b results for VIB7734, a treatment for cutaneous lupus erythematosus (CLE). Key findings include a safety profile comparable to placebo, significant depletion of plasmacytoid dendritic cells (pDCs) in both blood and skin, and clinically meaningful improvements in the Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) scores, with reductions of 4 points or more. The study, involving 31 patients, suggests potential for advancing into Phase 2 trials targeting autoimmune conditions driven by pDCs.
Viela Bio (Nasdaq: VIE) will host a webcast and conference call on May 13, 2020, at 5:00 p.m. ET to discuss its first quarter 2020 financial results and program highlights. The call will be accessible domestically at (877) 783-8848 or internationally at (631) 350-0960 using conference ID #: 3052446. The archived webcast will be available for replay approximately two hours after the event on the company's website. Viela Bio focuses on developing innovative treatments for autoimmune and severe inflammatory diseases.
Summary not available.